This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Retinal/ Chorioretinal Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Jasmine R. Elison, MD; David Cobrinik, MD, PhD; Nidia Claros, BS; David H. Abramson, MD; Thomas C. Lee, MD

Arch Ophthalmol. 2006;124:1269-1275.

Purpose  To determine the efficacy of inducing p53-mediated cell death in retinoblastoma cells by Nutlin 3A, a small molecule HDM2 inhibitor.

Methods  Retinoblastoma cell lines WERI-RB-1 and Y79 were treated with Nutlin 3A. Cell viability assays, Western blot analyses, confocal microscopy, and flow cytometry were performed to measure cell survival, p53 protein levels, activation of downstream targets, and apoptosis. To determine whether the effects of Nutlin 3A were p53-dependent, cell viability assays were performed on Y79 cells expressing short interfering RNA (siRNA) against p53.

Results  Nutlin 3A induced cell death in Y79 and WERI-RB-1 in the 5- to 10-µM dose range. Treated cells demonstrated increased protein levels of p53 and the p53 targets p21 and HDM2. Phosphorylation of p53-serine-15, a marker for activation of p53 via genotoxic mechanisms, was absent. Y79 cells expressing siRNA against p53 demonstrated resistance to Nutlin 3A.

Conclusions  Nutlin 3A induced p53-mediated apoptosis in a dose-dependent, nongenotoxic fashion in 2 retinoblastoma cell lines.

Clinical Relevance  Nutlin 3A is effective against retinoblastoma cells in a nongenotoxic manner. Because the mutagenic effects of radiation and chemotherapy may increase risks of secondary tumor formation, targeted p53 activation may be a safer alternative treatment for retinoblastoma in the future.

Author Affiliations: Department of Ophthalmology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY (Drs Elison, Cobrinik, and Lee and Ms Claros); and Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan-Kettering Hospital, New York, NY (Dr Abramson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Revisiting Old Drugs as Novel Agents for Retinoblastoma: In Vitro and In Vivo Antitumor Activity of Cardenolides
Antczak et al.
IOVS 2009;50:3065-3073.
ABSTRACT | FULL TEXT  

Retinoblastoma: Review of Current Management
Chintagumpala et al.
The Oncologist 2007;12:1237-1246.
ABSTRACT | FULL TEXT  

Functional p53 Signaling in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas: Implications for Therapy
Petre et al.
J. Virol. 2007;81:1912-1922.
ABSTRACT | FULL TEXT